Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT07242560
Active, not recruiting Observational

Epidural Catheter and Port-Related Infections in Pain Clinic Patients

NCT07242560 · tracked via the Priya Life Science Turkey tracker
Sponsor
Mesut Bakır
Phase
Observational
Started
2002-01-01
Last updated
2025-11-21

Condition(s) studied

Epidural Catheter-Related InfectionHospital-Acquired InfectionProcedural Complication

Study summary

This retrospective observational study aims to evaluate the incidence and risk factors of infection associated with epidural catheter and port applications performed in the Pain Clinic of Mersin University Faculty of Medicine. Data from patients who underwent epidural catheter or port placement between January 2002 and January 2025 will be analyzed.

Demographic data, catheter duration, insertion level, type of device, clinical indication, and microbiological culture results will be examined to determine factors influencing infection development. The study seeks to identify common pathogens and assess potential relationships between procedural characteristics and infection risk.

The ultimate goal of this research is to contribute to improving infection prevention strategies and ensuring patient safety in interventional pain management practices.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients aged 18 years and older. * Patients who underwent epidural catheter or epidural port application at Mersin University Pain Clinic between January 1, 2002 and January 1, 2025. * Complete clinical records including demographic data, procedural details, and culture results available for review. Exclusion Criteria: * Patients with incomplete or missing procedural or infection data. Patients whose records do not include culture or infection status documentation. Patients younger than 18 years old.

Primary outcome measure(s)

  • Incidence of Infection Associated With Epidural Catheter or Port Use — From date of catheter or port placement until device removal or completion of follow-up (within study period January 2002-January 2025).
    The proportion of patients who developed infection following epidural catheter or port placement, confirmed either clinically or microbiologically (positive culture from catheter tip or port site).

Trial sites (1)

FacilityCityRegionStatus
Mersin University Faculty of Medicine, Department of Algology Mersin Mersin

More Mesut Bakır trials in Turkey

Comparison of Two Types of Radiofrequency Treatment for Trigeminal Neuralgia Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07242560 on ClinicalTrials.gov ↗ ← All trials in Turkey